Sangamo Therapeutics Inc (NAS:SGMO)
$ 2.16 0.42 (24.14%) Market Cap: 449.76 Mil Enterprise Value: 363.62 Mil PE Ratio: 0 PB Ratio: 19.64 GF Score: 42/100

Sangamo Therapeutics Inc at Morgan Stanley Healthcare Conference Transcript

Sep 09, 2019 / 12:10PM GMT
Release Date Price: $10.39 (-2.17%)
Unidentified Analyst

(technical difficulty)

Therapeutics.

Before we get into the Q&A, I have to read a disclosure. So before we get started, I just need to let you know that for all important disclosures, please see the Morgan Stanley research disclosures website at www.morganstanley.com/researchdisclosures.

Okay. Sandy, thank you for being with us.

Alexander D. Macrae
Sangamo Therapeutics, Inc. - CEO, President & Director

My pleasure.

Unidentified Analyst

So before we get into kind of program-specific Q&A, maybe it's good if you could just provide a couple of minutes of opening remarks about some of your key corporate highlights and then we can go from there.

Alexander D. Macrae
Sangamo Therapeutics, Inc. - CEO, President & Director

Thank you. So Sangamo is a fascinating company. It's a genomic medicine company, and we can do gene therapy, cell

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot